189 related articles for article (PubMed ID: 36036468)
1. Pharmacologic therapeutic options for sexual dysfunction.
Burton CS; Mishra K
Curr Opin Obstet Gynecol; 2022 Dec; 34(6):402-408. PubMed ID: 36036468
[TBL] [Abstract][Full Text] [Related]
2. Medical Treatment of Female Sexual Dysfunction.
Nappi RE; Tiranini L; Martini E; Bosoni D; Righi A; Cucinella L
Urol Clin North Am; 2022 May; 49(2):299-307. PubMed ID: 35428435
[TBL] [Abstract][Full Text] [Related]
3. Flibanserin for Hypoactive Sexual Desire Disorder: An Open-Label Safety Study.
Simon JA; Derogatis L; Portman D; Brown L; Yuan J; Kissling R
J Sex Med; 2018 Mar; 15(3):387-395. PubMed ID: 29502984
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy for Sexual Dysfunction in Women.
Lee JH; Lee JE; Harsh V; Clayton AH
Curr Psychiatry Rep; 2022 Feb; 24(2):99-109. PubMed ID: 35102537
[TBL] [Abstract][Full Text] [Related]
5. Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder: Results of the PLUMERIA Study.
Portman DJ; Brown L; Yuan J; Kissling R; Kingsberg SA
J Sex Med; 2017 Jun; 14(6):834-842. PubMed ID: 28583342
[TBL] [Abstract][Full Text] [Related]
6. Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.
Dhanuka I; Simon JA
Expert Opin Pharmacother; 2015; 16(16):2523-9. PubMed ID: 26395164
[TBL] [Abstract][Full Text] [Related]
7. [Female sexual dysfunction: Drug treatment options].
Alcántara Montero A; Sánchez Carnerero CI
Semergen; 2016; 42(5):e33-7. PubMed ID: 27041639
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis.
Jaspers L; Feys F; Bramer WM; Franco OH; Leusink P; Laan ET
JAMA Intern Med; 2016 Apr; 176(4):453-62. PubMed ID: 26927498
[TBL] [Abstract][Full Text] [Related]
9. Flibanserin: a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women.
Clayton AH; Dennerstein L; Pyke R; Sand M
Womens Health (Lond); 2010 Sep; 6(5):639-53. PubMed ID: 20887163
[TBL] [Abstract][Full Text] [Related]
10. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
Althof S; Derogatis LR; Greenberg S; Clayton AH; Jordan R; Lucas J; Spana C
J Sex Med; 2019 Aug; 16(8):1226-1235. PubMed ID: 31277966
[TBL] [Abstract][Full Text] [Related]
11. Testosterone therapy in women: a review.
Bolour S; Braunstein G
Int J Impot Res; 2005; 17(5):399-408. PubMed ID: 15889125
[TBL] [Abstract][Full Text] [Related]
12. Flibanserin for female sexual dysfunction.
Reviriego C
Drugs Today (Barc); 2014 Aug; 50(8):549-56. PubMed ID: 25187905
[TBL] [Abstract][Full Text] [Related]
13. Safety of Flibanserin in Women Treated With Antidepressants: A Randomized, Placebo-Controlled Study.
Clayton AH; Croft HA; Yuan J; Brown L; Kissling R
J Sex Med; 2018 Jan; 15(1):43-51. PubMed ID: 29289374
[TBL] [Abstract][Full Text] [Related]
14. Lumping, Splitting, and Treating: Therapies Are Needed for Women With Overlapping Sexual Dysfunctions.
Pyke RE; Clayton AH
Sex Med Rev; 2019 Oct; 7(4):551-558. PubMed ID: 31204297
[TBL] [Abstract][Full Text] [Related]
15. Understanding the Role of Serotonin in Female Hypoactive Sexual Desire Disorder and Treatment Options.
Croft HA
J Sex Med; 2017 Dec; 14(12):1575-1584. PubMed ID: 29198512
[TBL] [Abstract][Full Text] [Related]
16. Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment.
Kingsberg SA; Simon JA
J Womens Health (Larchmt); 2020 Aug; 29(8):1101-1112. PubMed ID: 32460605
[TBL] [Abstract][Full Text] [Related]
17. The safety of testosterone therapy in women.
Al-Imari L; Wolfman WL
J Obstet Gynaecol Can; 2012 Sep; 34(9):859-865. PubMed ID: 22971455
[TBL] [Abstract][Full Text] [Related]
18. The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
Kingsberg SA; Simon JA; Goldstein I
J Sex Med; 2008 Sep; 5 Suppl 4():182-93; quiz 193. PubMed ID: 18783534
[TBL] [Abstract][Full Text] [Related]
19. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
Diamond LE; Earle DC; Heiman JR; Rosen RC; Perelman MA; Harning R
J Sex Med; 2006 Jul; 3(4):628-638. PubMed ID: 16839319
[TBL] [Abstract][Full Text] [Related]
20. Editorial comments on "the current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women".
Goldstein I
J Sex Med; 2008 Sep; 5 Suppl 4():177-8. PubMed ID: 18783531
[No Abstract] [Full Text] [Related]
[Next] [New Search]
